Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Lonigutamab ugodotin by Laboratoires Pierre Fabre for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Lonigutamab ugodotin is under clinical development by Laboratoires Pierre Fabre and currently in Phase II for Squamous Non-Small Cell Lung...
Lonigutamab ugodotin by Laboratoires Pierre Fabre for Laryngeal Cancer: Likelihood of Approval
Lonigutamab ugodotin is under clinical development by Laboratoires Pierre Fabre and currently in Phase II for Laryngeal Cancer. According to...
Lonigutamab ugodotin by Laboratoires Pierre Fabre for Soft Tissue Sarcoma: Likelihood of Approval
Lonigutamab ugodotin is under clinical development by Laboratoires Pierre Fabre and currently in Phase II for Soft Tissue Sarcoma. According...
Lonigutamab ugodotin by Laboratoires Pierre Fabre for Breast Cancer: Likelihood of Approval
Lonigutamab ugodotin is under clinical development by Laboratoires Pierre Fabre and currently in Phase II for Breast Cancer. According to...
Lonigutamab ugodotin by Laboratoires Pierre Fabre for Soft Tissue Sarcoma: Likelihood of Approval
Lonigutamab ugodotin is under clinical development by Laboratoires Pierre Fabre and currently in Phase II for Soft Tissue Sarcoma. According...